Hnrnpa1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
HNRNPA1 (Heterogeneous Nuclear Ribonucleoprotein A1) is an RNA-binding protein involved in multiple aspects of RNA metabolism, including splicing, transport, and stability. It contains prion-like domains that can form liquid-liquid phase separations, and pathogenic mutations lead to ALS/FTD through toxic aggregation.
HNRNPA1 contains several functional domains:
- RNA Recognition Motifs (RRMs): Two RRMs (RRM1 and RRM2) that bind RNA
- Prion-like domain (PrLD): C-terminal low-complexity domain prone to aggregation
- Glycine-rich region: Involved in protein-protein interactions
The prion-like domain is critical for both normal function (stress granule formation) and disease (pathological aggregation).
- Component of the spliceosomal complex
- Regulates alternative splicing of neuronal transcripts
- Essential for proper mRNA maturation
- Facilitates mRNA nuclear export
- Directs mRNAs to specific cellular compartments
- Participates in dendritic RNA localization
- Forms stress granules under cellular stress
- Regulates translation during stress conditions
- Part of cytoplasmic RNA granules
Mutations in the prion-like domain of HNRNPA1 cause disease through several mechanisms:
- Increased aggregation propensity: Mutations lower the threshold for phase transition
- Altered stress granule dynamics: Mutant proteins form persistent granules
- Loss of nuclear function: Impaired splicing of essential transcripts
- Sequestration of normal proteins: Aggregates trap other RNA-binding proteins
| Mutation |
Effect |
| D262V |
Increased PrLD aggregation |
| G295S |
Enhanced stress granule formation |
| G298R |
Disrupted RNA binding |
| D314V |
Accelerated aggregation |
| F316L |
Altered phase separation |
| Strategy |
Approach |
Status |
| ASO therapy |
Reduce mutant expression |
Preclinical |
| Small molecules |
Inhibit aggregation |
Discovery |
| Gene therapy |
Deliver wild-type protein |
Preclinical |
¶ RNA Binding and Splicing Regulation
HNRNPA1 is a key regulator of alternative splicing:
- Splicing factor activity: Binds to pre-mRNA sequences
- Exon skipping: Promotes or inhibits specific exon inclusion
- Tissue-specific regulation: Different splicing patterns in various tissues
- Disease-associated splicing: Dysregulation in neurodegeneration
HNRNPA1 regulates splicing of:
- Tau (MAPT): Alternative splicing of exon 10
- APP: Alternative processing
- NF-L: Neurofilament light chain
- SMN2: Splicing modification in SMA
HNRNPA1 facilitates mRNA export from nucleus:
- mRNP complex formation: Packaging with other hnRNPs
- Nuclear pore interaction: Facilitates transport
- Translation regulation: Links processing to translation
Under cellular stress, HNRNPA1:
- Recruits to stress granules
- Participates in RNA granule assembly
- Protects mRNA during stress
- Antisense oligonucleotides: Reduce mutant HNRNPA1 expression
- Small molecule modulators: Target splicing function
- Gene therapy: Viral vector delivery approaches
- Chemotherapy targets: Synthetic lethal approaches
- Splicing modulators: FDA-approved drugs (e.g., spliceosome modulators)
- CLIP-seq: Mapping RNA binding sites
- iCLIP: High-resolution protein-RNA interactions
- RNA-seq: Global splicing analysis
- Proteomics: Interaction partner identification
The study of Hnrnpa1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Dreyfuss G, et al. (2002) Messenger-RNA-binding proteins and the diseases. Nature 419:745-751. PMID:12403497
- Kim HJ, et al. (2013) Mutations in prion-like domains in hnRNPA1 and hnRNPA2B1 cause ALS/FTD. Neuron 79:980-991. PMID:23921701
- Martinez FJ, et al. (2016) Protein-RNA networks in ALS. Neuron 90:207-223. PMID:27117757
- Benajiba L, et al. (2015) HNRNPA1 mutations in ALS/FTD. Neurology 84:765-773. PMID:25589670
- Liu Q, et al. (2017) hnRNP A1 and ALS. Acta Neuropathol 133:361-377. PMID:28102437
- Wang I, et al. (2018) Structure of hnRNP A1 RRM1-2 bound to DNA. Nat Commun 9:1149. PMID:29563552
- Geuens T, et al. (2016) hnRNP proteins in disease. Wiley Interdiscip Rev RNA 7:615-634. PMID:27023447
- Conlon EG, et al. (2019) ALS-associated hnRNPA1 mutations. Neuron 101:831-844. PMID:30620565